|
1
|
Yokota T, Hatooka S, Ura T, Abe T,
Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Yatabe Y, et
al: Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction
chemotherapy for locally advanced borderline-resectable T4
esophageal cancer. Anticancer Res. 31:3535–3541. 2011.PubMed/NCBI
|
|
2
|
Tamura S, Imano M, Takiuchi H, Kobayashi
K, Imamoto H, Miki H, Goto Y, Aoki T, Peng YF, Tsujinaka T, et al:
Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for
metastatic esophageal cancer (OGSG 0403). Anticancer Res.
32:1403–1408. 2012.PubMed/NCBI
|
|
3
|
Sugawara M, Katada C, Katada N, Takahashi
K, Higuchi K, Komori S, Moriya H, Ishiyama H, Yamashita K,
Sakuramoto S, et al: Retrospective evaluation of adverse events of
neoadjuvant or induction chemotherapy with docetaxel, cisplatin,
and 5-fluorouracil in esophageal squamous cell carcinoma.
Esophagus. 10:65–69. 2013. View Article : Google Scholar
|
|
4
|
Stoehlmacher J, Park DJ, Zhang W, Yang D,
Groshen S, Zahedy S and Lenz HJ: A multivariate analysis of genomic
polymorphisms: Prediction of clinical outcome to 5-FU/oxaliplatin
combination chemotherapy in refractory colorectal cancer. Br J
Cancer. 91:344–354. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Paré L, Marcuello E, Altés A, del Río E,
Sedano L, Salazar J, Cortés A, Barnadas A and Baiget M:
Pharmacogenetic prediction of clinical outcome in advanced
colorectal cancer patients receiving oxaliplatin/5-fluorouracil as
first-line chemotherapy. Br J Cancer. 99:1050–1055. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Deenen MJ, Cats A, Beijnen JH and
Schellens JH: Part 4: Pharmacogenetic variability in anticancer
pharmacodynamic drug effects. Oncologist. 16:1006–1020. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bowden NA: Nucleotide excision repair: Why
is it not used to predict response to platinum-based chemotherapy?
Cancer Lett. 346:163–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu JJ, Mu C, Lee KB, Okamoto A, Reed EL,
Bostick-Bruton F, Mitchell KC and Reed E: A nucleotide polymorphism
in ERCC1 in human ovarian cancer cell lines and tumor tissues.
Mutat Res. 382:13–20. 1997.PubMed/NCBI
|
|
9
|
Yang Y and Xian L: The association between
the ERCC1/2 polymorphisms and the clinical outcomes of the
platinum-based chemotherapy in non-small cell lung cancer (NSCLC):
A systematic review and meta-analysis. Tumor Biol. 35:2905–2921.
2014. View Article : Google Scholar
|
|
10
|
Zhang G, Guan Y, Zhao Y, van der Straaten
T, Xiao S, Xue P, Zhu G, Liu Q, Cai Y, Jin C, et al: ERCC2/XPD
Lys751Gln alter DNA repair efficiency of platinum-induced DNA
damage through P53 pathway. Chem Biol Interact. 263:55–65. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yin M, Yan J, Martinez-Balibrea E,
Graziano F, Lenz HJ, Kim HJ, Robert J, Im SA, Wang WS,
Etienne-Grimaldi MC and Wei Q: ERCC1 and ERCC2 polymorphisms
predict clinical outcomes of oxaliplatin-based chemotherapies in
gastric and colorectal cancer: A systemic review and meta-analysis.
Clin Cancer Res. 17:1632–1640. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tew KD: Redox in redux: Emergent roles for
glutathione S-transferase P (GSTP) in regulation of cell signaling
and S-glutathionylation. Biochem Pharmacol. 73:1257–1269. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moyer AM, Salavaggione OE, Wu TY, Moon I,
Eckloff BW, Hildebrandt MA, Schaid DJ, Wieben ED and Weinshilboum
RM: Glutathione s-transferase p1: Gene sequence variation and
functional genomic studies. Cancer Res. 68:4791–4801. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stoehlmacher J, Park DJ, Zhang W, Groshen
S, Tsao-wei DD, Yu MC and Lenz HJ: Association between glutathione
S-transferase P1, T1, and M1 genetic polymorphism and survival of
patients with metastatic colorectal cancer. J Natl Cancer Inst.
94:936–942. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Z, Chen JQ, Liu JL, Qin XG and Huang
Y: Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical
outcomes of gastric cancer patients treated with
platinum/5-Fu-based chemotherapy: A systematic review. BMC
Gastroenterol. 12:1372012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Popat S, Matakidou A and Houlston RS:
Thymidylate synthase expression and prognosis in colorectal cancer:
A systematic review and meta-analysis. J Clin Oncol. 22:529–536.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lurje G, Manegold PC, Ning Y, Pohl A,
Zhang W and Lenz HJ: Thymidylate synthase gene variations:
Predictive and prognostic markers. Mol Cancer Ther. 8:1000–1007.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mandola MV, Stoehlmacher J, Zhang W,
Groshen S, Yu MC, Iqbal S, Lenz HJ and Ladner RD: A 6 bp
polymorphism in the thymidylate synthase gene causes message
instability and is associated with decreased intratumoral TS mRNA
levels. Pharmacogenetics. 14:319–327. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dotor E, Cuatrecases M, Martínez-Iniesta
M, Navarro M, Vilardell F, Guinó E, Pareja L, Figueras A, Molleví
DG, Serrano T, et al: Tumor thymidylate synthase 1494del6 genotype
as a prognostic factor in colorectal cancer patients receiving
fluorouracil-based adjuvant treatment. J Clin Oncol. 24:1603–1611.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Van Cutsem E, Moiseyenko VM, Tjulandin S,
Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi
E, et al: Phase III study of docetaxel and cisplatin plus
fluorouracil compared with cisplatin and fluorouracil as first-line
therapy for advanced gastric cancer: A report of the V325 study
group. J Clin Oncol. 24:4991–4997. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Posner MR, Hershock DM, Blajman CR,
Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM,
Cullen K, Ervin TJ, et al: Cisplatin and fluorouracil alone or with
docetaxel in head and neck cancer. N Engl J Med. 357:1705–1715.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Melchardt T, Hufnagl C, Magnes T, Weiss L,
Hutarew G, Neureiter D, Schlattau A, Moser G, Gaggl A, Tränkenschuh
W, et al: CYP39A1 polymorphism is associated with toxicity during
intensive induction chemotherapy in patients with advanced head and
neck cancer. BMC Cancer. 15:7252015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bender R and Lange S: Adjusting for
multiple testing-when and how? J Clin Epidemiol. 54:343–349. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Graffelman J: Exploring diallelic genetic
markers: The HardyWeinberg package. J Stat Softw. 64:1–23. 2015.
View Article : Google Scholar
|
|
26
|
1000 Genomes Project Consortium, . Auton
A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini
JL, McCarthy S, McVean GA and Abecasis GR: A global reference for
human genetic variation. Nature. 526:68–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matsumoto A, Nishikawa K, Yuda M, Tanaka
Y, Tanishima Y, Arakawa Y, Ishibashi Y, Sakuyama T, Omura N,
Mitsumori N, et al: Early response of esophageal cancer to
neoadjuvant chemotherapy with docetaxel-cisplatin-5-Fluorouracil
represents sensitivity: A phase II study. Anticancer Res.
36:1937–1942. 2016.PubMed/NCBI
|
|
28
|
Noronha V, Joshi A, Jandyal S, Jambhekar N
and Prabhash K: High pathologic complete remission rate from
induction docetaxel, platinum and fluorouracil (DCF) combination
chemotherapy for locally advanced esophageal and junctional cancer.
Med Oncol. 31:1882014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Arakawa Y, Tamura M, Sakuyama T, Aiba K,
Eto S, Yuda M, Tanaka Y, Matsumoto A and Nishikawa K: Early
measurement of urinary N-acetyl-β-glucosaminidase helps predict
severe hyponatremia associated with cisplatin-containing
chemotherapy. J Infect Chemother. 21:502–506. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu N, Roth MJ, Polymeropolous M, Tang ZZ,
Emmert-Buck MR, Wang QH, Goldstein AM, Feng SS, Dawsey SM, Ding T,
et al: Identification of novel regions of allelic loss from a
genomewide scan of esophageal squamous-cell carcinoma in a
high-risk Chinese population. Genes Chromosomes Cancer. 27:217–228.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nakakuki K, Imoto I, Pimkhaokham A, Fukuda
Y, Shimada Y, Imamura M, Amagasa T and Inazawa J: Novel targets for
the 18p11.3 amplification frequently observed in esophageal
squamous cell carcinomas. Carcinogenesis. 23:19–24. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cortejoso L, García MI, García-Alfonso P,
González-Haba E, Escolar F, Sanjurjo M and López-Fernández LA:
Differential toxicity biomarkers for irinotecan- and
oxaliplatin-containing chemotherapy in colorectal cancer. Cancer
Chemother Pharmacol. 71:1463–1472. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Deenen MJ, Meulendijks D, Boot H, Legdeur
MC, Beijnen JH, Schellens JH and Cats A: Phase 1a/1b and
pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in
patients with advanced cancer of the stomach or the
gastroesophageal junction. Cancer Chemother Pharmacol.
76:1285–1295. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lambrechts S, Lambrechts D, Despierre E,
Van Nieuwenhuysen E, Smeets D, Debruyne PR, Renard V, Vroman P,
Luyten D, Neven P, et al: Genetic variability in drug transport,
metabolism or DNA repair affecting toxicity of chemotherapy in
ovarian cancer. BMC Pharmacol Toxicol. 16:22015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lecomte T, Landi B, Beaune P, Laurent-Puig
P and Loriot MA: Glutathione S-transferase P1 polymorphism
(Ile105Val) predicts cumulative neuropathy in patients receiving
oxaliplatin-based chemotherapy. Clin Cancer Res. 12:3050–3056.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McLeod HL, Sargent DJ, Marsh S, Green EM,
King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP,
Thibodeau SN, et al: Pharmacogenetic predictors of adverse events
and response to chemotherapy in metastatic colorectal cancer:
results from North American gastrointestinal intergroup trial
N9741. J Clin Oncol. 28:3227–3233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li QF, Yao RY, Liu KW, Lv HY, Jiang T and
Liang J: Genetic polymorphism of GSTP1: Prediction of clinical
outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric
cancer. J Korean Med Sci. 25:846–852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mir O, Alexandre J, Tran A, Durand JP,
Pons G, Treluyer JM and Goldwasser F: Relationship between GSTP1
Ile(105)Val polymorphism and docetaxel-induced peripheral
neuropathy: Clinical evidence of a role of oxidative stress in
taxane toxicity. Ann Oncol. 20:736–740. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu YP, Ling Y, Qi QF, Zhang YP, Zhang CS,
Zhu CT, Wang MH and Pan YD: Genetic polymorphisms of ERCC1-118,
XRCC1-399 and GSTP1-105 are associated with the clinical outcome of
gastric cancer patients receiving oxaliplatin-based adjuvant
chemotherapy. Mol Med Rep. 7:1904–1911. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Goekkurt E, Al-Batran SE, Hartmann JT,
Mogck U, Schuch G, Kramer M, Jaeger E, Bokemeyer C, Ehninger G and
Stoehlmacher J: Pharmacogenetic analyses of a phase III trial in
metastatic gastroesophageal adenocarcinoma with fluorouracil and
leucovorin plus either oxaliplatin or cisplatin: A study of the
arbeitsgemeinschaft internistische onkologie. J Clin Oncol.
27:2863–2873. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Song Y, Du Y, Zhou Q, Ma J, Yu J, Tao X
and Zhang F: Association of GSTP1 Ile105Val polymorphism with risk
of esophageal cancer: A meta-analysis of 21 case-control studies.
Int J Clin Exp Med. 7:3215–3224. 2014.PubMed/NCBI
|
|
42
|
Perazella MA: Onco-nephrology: Renal
toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol.
7:1713–1721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ulrich CM, Bigler J, Bostick R, Fosdick L
and Potter JD: Thymidylate synthase promoter polymorphism,
interaction with folate intake, and risk of colorectal adenomas.
Cancer Res. 62:3361–3364. 2002.PubMed/NCBI
|
|
44
|
Lecomte T, Ferraz JM, Zinzindohoué F,
Loriot MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R,
Beaune P and Laurent-Puig P: Thymidylate synthase gene polymorphism
predicts toxicity in colorectal cancer patients receiving
5-fluorouracil-based chemotherapy. Clin Cancer Res. 10:5880–5888.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhu S, Pabla N, Tang C, He L and Dong Z:
DNA damage response in cisplatin-induced nephrotoxicity. Arch
Toxicol. 89:2197–2205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bradbury PA, Kulke MH, Heist RS, Zhou W,
Ma C, Xu W, Marshall AL, Zhai R, Hooshmand SM, Asomaning K, et al:
Cisplatin pharmacogenetics, DNA repair polymorphisms, and
esophageal cancer outcomes. Pharmacogenet Genomics. 19:613–625.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yu HP, Wang XL, Sun X, Su YH, Wang YJ, Lu
B, Shi LY, Xiong CL, Li YY, Li F and Xu SQ: Polymorphisms in the
DNA repair gene XPD and susceptibility to esophageal squamous cell
carcinoma. Cancer Genet Cytogenet. 154:10–15. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li RZ and Sun J: Association between XPD
gene polymorphisms and esophageal squamous cell carcinoma. Mol Med
Rep. 7:674–678. 2013. View Article : Google Scholar : PubMed/NCBI
|
